Neuberger Berman Group
AVNR

Neuberger Berman Group’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Neuberger Berman Group’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-15,079
Closed -$51K – 1714
2013
Q4 		$51K Buy
+15,079
New +$62.3K ﹤0.01% 1602

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group's AVNR Position: Q1 2014 in Review

Neuberger Berman Group sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 15,079 shares — an estimated $51K sold.

Neuberger Berman Group first reported a position in AVNR in Q4 2013 and held it in 1 quarter. The position peaked at $51K in Q4 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • Neuberger Berman Group reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • Neuberger Berman Group sold 15,079 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $51K.
  • Neuberger Berman Group first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q4 2013 and held it in 1 quarter.
  • Neuberger Berman Group's AVANIR PHARMACEUTICALS, INC CL A position peaked at $51K in Q4 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on Neuberger Berman Group's 13F filing for Q1 2014, filed 5 May 2014.